Citations 1
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia
Fortuna, Gliceida Galarza , Peres, Lauren C. , Corraes, Andre De Menezes Silva , Hovanky, Vanna, Shune, Leyla , McGuirk, Joseph P. , Avilla, Gabriel De, Khouri, Jack , Dima, Danai , Gaballa, Mahmoud , Dhakal, Binod , Forsberg, Peter A. , Godara, Amandeep , Afrough, Aimaz , Anderson, Larry D. , Davis, James A. , Mann, Hashim , Purvey, Sneha , Clark, William , Htut, Myo, Ferreri, Christopher J. , Voorhees, Peter M. , Hashmi, Hamza , Patel, Krina K. , Sidana, Surbhi , Lin, Yi, Sborov, Douglas W. , Galarza Fortuna, Gliceida M , De Menezes Silva Corraes, Andre , McGuirk, Joseph , Khouri, Jack , Dima, Danai , Dhakal, Binod , Godara, Amandeep , Anderson, Larry D , Herr, Megan M. , Davis, James A , Mann, Hashim , Kocoglu, Mehmet H , Voorhees, Peter , Patel, Krina , Sidana, Surbhi , Hansen, Doris K , Sborov, Douglas W , Назаренко, Елена Борисовна , Avilla, Gabriel De, Clark, William, Htut, Myo , Beitinjaneh, Amer , Pereira, Denise L. , Kocoglu, Mehmet H. , Atrash, Shebli , Rossi, Adriana , Richard, Shambavi , Hansen, Doris K.
Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 6009-6018
10.1182/bloodadvances.2025016966
Abstract Despite significant therapeutic advances in multiple myeloma (MM), outcomes in patients with plasma cell leukemia (PCL) remain dismal. We conducted a multicenter retrospective analysis of patients with PCL who were treated with the B-cell maturation antigen–directed chimeric antigen receptor T-cell (CAR-T) products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We identified 34 patients; 19 patients received ide-cel and 15 received cilta-cel. With a median follow-up of 11.9 months, the overall median progression-free survival (mPFS) was 9.0 months (95% confidence interval [CI], 4-15) and the median overall survival (mOS) was 13.0 months (95% CI, 8 to not estimable [NE]). The 1-year cumulative incidence of progression or death was 72%, and the 1-year cumulative incidence of death was 47%. Patients who received cilta-cel had a longer mPFS (19.0 months vs 6.0 months) and mOS (>23 months [NE] vs 9.0 months) when compared with those treated with ide-cel. Similarly, the 1-year cumulative incidence of disease progression or death was 37.5% (95% CI, 17.4-68.5) with cilta-cel, whereas all patients treated with ide-cel progressed or died within 12 months of infusion. The rates of hematologic and nonhematologic toxicities were similar between patients treated with cilta-cel and those treated with ide-cel and were consistent with those reported in patients with MM. In this first multicenter study that evaluated patients with PCL who were treated with standard-of-care CAR-T products, we show that CAR-T is safe, feasible, and associated with improved outcomes when compared with historic standards.